SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company developing novel therapies for a broad range of cancer indications, will host a corporate update call on January 8, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 outlook.
The company's lead product candidate is Galinpepimut-S (GPS), licensed from Memorial Sloan Kettering Cancer Center, and it targets the WT1 protein, which is present in an array of tumor types.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.